Indeed, thanks to their amplified capability to produce cytokines upon CD16 stimulation, memory NK cells could participate to the development of adaptive anti-tumor immune responses, required for the long-term protection of treated patients (27–29). The gene discussed is FCGR3A; the disease is neoplasm.